New imatinib variant tested for CML: could it be better?
Disease control
Completed
This completed Phase 1 trial tested a new drug called IkT-001Pro in 64 healthy adults aged 18 to 55. The goal was to see if it works like the standard CML drug imatinib in the body. Participants took single doses of both drugs at different times to compare how they are absorbed a…
Phase: PHASE1 • Sponsor: Inhibikase Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC